Home › Blood Cancers › Tennessee › Nashville
Blood Cancers clinical trials in Nashville, TN
13 studies for Blood Cancers are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
RecruitingPhase 3
- Vanderbilt Health One Hundred Oaks Diagnostic ( Site 0060), Nashville
- Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0015), Nashville
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
RecruitingPhase 1
- Sarah Cannon Cancer Institute, Nashville
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RecruitingPhase 3
- Quetzal Site 12, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingPhase 3
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RecruitingPhase 1
- Vanderbilt University Medical Center, Nashville
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RecruitingPhase 1
- Sarah Cannon Research Institute - Oncology Partners, Nashville
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
- Vanderbilt University, Ingram Cancer Center, Nashville
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Vanderbilt University, Nashville
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
RecruitingPhase 3
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RecruitingPhase 1
- TriStar Bone Marrow Transplant, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RecruitingPhase 1/2
- SCRI Oncology Partners, Nashville
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RecruitingPhase 1
- TriStar Bone Marrow Transplant, Nashville
Blood Cancers trials in other cities
- Houston, TX46 studies
- New York City, NY26 studies
- Boston, MA25 studies
- Washington, DC19 studies
- Seattle, WA18 studies
- Baltimore, MD18 studies
- Los Angeles, CA17 studies
- Durham, NC16 studies
- Chicago, IL15 studies
- Philadelphia, PA14 studies
- Columbus, OH13 studies
- Edison, NJ13 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer97 studies
- Breast Cancer81 studies
- Metastatic Cancer70 studies
- Colorectal Cancer69 studies
- Cancer (all types)65 studies
- Ovarian Cancer49 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Head and Neck Squamous Cell Carcinoma39 studies
- Pancreatic Cancer39 studies
- Endometrial Cancer38 studies
- Melanoma33 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.